Interdisciplinary cancer research, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Nature Nanotechnology, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 1, 2024
Language: Английский
Citations
12
Bioactive Materials, Journal Year: 2024, Volume and Issue: 43, P. 406 - 422
Published: Oct. 1, 2024
Language: Английский
Citations
9
International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: 671, P. 125202 - 125202
Published: Jan. 10, 2025
Over the past two decades, extensive research has focused on both fundamental and applied aspects of nanomedicine, driven by compelling advantages that nanoparticles offer over their bulk counterparts. Despite this intensive effort, fewer than 100 nanomedicines have been approved U.S. Food Drug Administration European Medicines Agency since 1989. This disparity highlights a substantial gap in translational research, reflecting disconnect between prolific nanomedicine limited number products successfully reach sustain themselves market. For instance, DepoCyt, which received FDA approval 1999 for treatment lymphomatous meningitis, was discontinued 2017 due to persistent manufacturing issues. To address similar challenges, review aims identify analyse issues related formulation design nanomedicines. It provides an overview most prevalent technologies excipients used production, followed critical evaluation clinical translatability. Furthermore, presents strategies rational optimization manufacturing, adhering principles quality-by-design quality risk management.
Language: Английский
Citations
1
Expert Opinion on Drug Delivery, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 11, 2025
Introduction mRNA therapeutics were a niche area in drug development before COVIDvaccines. Now they are used vaccine development, for non-viral therapeuticgenome editing, vivo chimericantigen receptor T (CAR T) celltherapies and protein replacement. mRNAis large, charged, easily degraded by nucleases. It cannot get into cells,escape the endosome, be translated to disease-modifying without adelivery system such as lipid nanoparticles (LNPs).
Language: Английский
Citations
1
Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)
Published: Jan. 21, 2025
Targeted protein delivery with nanocarriers holds significant potential to enhance therapeutic outcomes by precisely directing proteins specific organs or tissues. However, the complex interactions between and biological environment pose considerable challenges in designing effective targeted vehicles. In this study, we address challenge leveraging DNA-barcoded high-throughput screening. We construct a nanocapsule library via in-situ polymerization, incorporating various monomers create nanocapsules unique surface properties. vitro vivo screening, using female mice, identify high cell association different biodistribution. Our investigation into kidney-enriched highlights crucial role of polymer composition biodistribution, demonstrating engineering for precise control over nanoparticle distribution. The successfully delivers catalase, showcasing its mitigating cisplatin-induced acute kidney injury. Overall, our study presents an approach identifying vehicles, capacity broaden application as agents research tools. development requires methods screening vivo. Here authors develop method biodistributions, demonstrate catalase kidneys
Language: Английский
Citations
1
Advanced Materials, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 9, 2025
Lipid nanoparticles (LNPs) with highly efficient and specific extrahepatic targeting abilities are promising in gene delivery, the lipopeptides (LPs) excellent designability functionality expected to empower construction of functional LNPs. This study aims develop ionizable components that accurately match different lipid systems through modular design LPs. Based on this, a lipopeptide-based organ-specific (POST) LNP screening strategy is constructed, which lysine-histidine-based (KH-LPs) designed as components. The optimal KH-LP screened vitro shows siRNA/mRNA transfecting ability various hard-to-transfect cell lines. Compared classic LNPs, POST LNPs vivo achieve even higher (or at least comparable) efficiency specificity delivering mRNA siRNA lung, liver, spleen, respectively. structure-activity relationship (SAR) proves regulation LP structures can provide for systems, demonstrating potential this developing selective open up more possibilities therapy.
Language: Английский
Citations
1
Advanced Science, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 18, 2025
Abstract Targeted delivery of mRNA with lipid nanoparticles (LNPs) holds great potential for treating pulmonary diseases. However, the lack rational design principles efficient lung‐homing lipids hinders prevalence therapeutics in this organ. Herein, combinatorial screening structure‐function analysis is applied to rationalize strategy nonpermanently charged lung‐targeted ionizable lipids. It discovered that carrying N‐methyl and secondary amine groups heads, three tails originated from epoxyalkanes, exhibiting superior selectivity efficiency. Representative systematically variation chemical structures are selected study well‐known but still puzzling “protein corona” adsorbed on surface LNPs. In addition commonly used corona‐biomarker vitronectin, other arginine‐glycine‐aspartic acid (RGD)‐rich proteins usually involved collagen‐containing extracellular matrix, such as fibrinogen fibronectin have also been identified a strong correlation lung tropism. This work provides insight into lung‐targeting reveals previously unreported function RGD‐rich protein corona
Language: Английский
Citations
1
Nature Protocols, Journal Year: 2025, Volume and Issue: unknown
Published: March 11, 2025
Language: Английский
Citations
1
ACS Nano, Journal Year: 2025, Volume and Issue: unknown
Published: April 7, 2025
Nanoparticles (NPs) have been extensively researched for targeted diagnostic imaging and drug delivery, yet their clinical translation remains limited, with only a few achieving Food Drug Administration approval. This limited success is primarily due to challenges in precise organ- or tissue-specific targeting, which arise from off-target tissue accumulation suboptimal clearance profiles. Herein we examine the critical role of physicochemical properties, including size, surface charge, shape, elasticity, hardness, density, governing biodistribution, targetability, NPs. We highlight recent advancements engineering NPs showcasing both significant progress remaining field nanomedicine. Additionally, discuss emerging tools technologies that are being developed address these challenges. Based on insights materials science, biomedical engineering, computational biology, research, propose key design considerations next-generation nanomedicines enhanced organ selectivity.
Language: Английский
Citations
1
Nano Letters, Journal Year: 2024, Volume and Issue: 24(26), P. 8080 - 8088
Published: June 18, 2024
Among various mRNA carrier systems, lipid nanoparticles (LNPs) stand out as the most clinically advanced. While current clinical trials of mRNA/LNP therapeutics mainly address liver diseases, potential therapy extends far beyond─yet to be unraveled. To fully unlock promises therapy, there is an urgent need develop safe and effective LNP systems that can target extrahepatic organs. Here, we report on development sulfonium (sLNPs) for systemic delivery lungs. sLNP effectively specifically delivered lungs following intravenous administration in mice. No evidence lung inflammation or toxicity major organs was induced by sLNP. Our findings demonstrated newly developed lung-specific platform both efficacious. It holds great promise advancing new mRNA-based therapies treatment lung-associated diseases conditions.
Language: Английский
Citations
8